Biotech is big in the world of SPACs once again. Half of the SPACs that have managed to IPO in the second half of October are specifically targeting the industry and three biotech deals have been announced since the start of the month. More
Another SPAC has made it through the IPO slowdown, but its team has once again made some considerable concessions to get it done. In the case of BHAV II (NASDAQ:BHAIU), the sponsor only overfunded its trust to 100. More
BHAV Acquisition Corp. II (NASDAQ:BHAIU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol "BHAIU" on Thursday, October 29, 2026. More
As yesterday saw the first debut of a SPAC IPO in nearly two weeks, Heroic Empire Acquisition Limited also broke the silence on the new filings front. More
Heroic Empire has filed for a $100 million IPO in what is the first new SPAC S-1 to hit the SEC in two weeks. Well, "new" is perhaps a misnomer in this case, as the team previously filed to IPO a SPAC under the same name back in 2022. More
The 11-day drought of SPAC IPOs is set to be broken later today as SPACCircle (NASDAQ:SCQCU) priced its $100 million offering overnight, but its terms reveal how generous teams have to be towards investors in order to get through in certain corners of the market. More
SPACCircle Acquisition Corp. (NASDAQ:SCQCU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol "SCQCU" on Tuesday, October 27, 2026. More
Amanat (NASDAQ:AMAN) has entered into a definitive agreement to combine with biotech firm Corxel Pharmaceuticals at an enterprise value of $228 million. Corxel is developing an oral GLP-1 weight-loss drug as well as other potential treatments. More
With just one week left in October, the month has currently represented a slowdown in SPAC IPOs, with just four teams pricing their vehicles since October 1. More